Examiner

Signature

PTO/SB/08a (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	_	Under the Pap	erwork	Reduction Act of 1995, no perso	ns are required to respond to a collecti	on of information unless it contains a valid OMB control nur		
1	Substitute	for form 1449A/PTC)		Complete if Known			
					Application Number	10/528,577		
				CLOSURE	Filing Date	March 21, 2005		
	STAT	EMENT B	ΥΑ	PPLICANT	First Named Inventor	Ulrich Speck et al.		
					Art Unit	March 21, 2005		
		(Use as many she	ets as	necessary)	Examiner Name	Laura A. Bouchelle		
Ū	Sheet	1	of	9	Attorney Docket Number	WEICKM-0044		

U.S. PATENT DOCUMENTS

			U.S. F/	ALEMI D	OCOM	INIO		
Examiner Initials *	Cite No	Document Number Number - Kind Code ² (if known)	Publicat MM-DI	ion Date 2-YYYY	Name of	Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Passages or Relevan Flaures Appear	Relevant it
	A1	4 776 337	10-11-1988		Р	ALMAZ ET AL.	r gui es Appeal	
	A2	4 217 894	08-19	-1990	FB	ANETZKI ET AL.		
	A3	4 997 643	03-05			ARTAIN ET AL.		
	A4	5 306 286	10-22	-1991		STACK ET AL.		
	A5	5 102 402		-1992		DROB ET AL.		
	A6	5 789 018	08-04	-1992	FN	GELSON ET AL.		
	A7	5 157 049	10-20	-1992	В	UDIGER ET AL.		
	A8	5 176 626	01-05	-1993	SO	HENDRA ET AL.		
	A9	5 234 456		-1993		STRIN, THOMAS A		
	A10	5 629 881	05-13	-1997		LEEB ET AL.		
	A11	5 980 972		-1999		DING ET AL.		
	A12	6 013 092		-2000	DEH	DASHTIAN ET AL.		
	A13	6 071 285	06-06	-2000	LA	SHINSKI ET AL.		
	A14	2001 0037140	11-01	-2001		AUDOIN ET AL.		
	A15	2002 0098278	07-25	-2002		BATES ET AL.		
	A16	2003 007944	01-09	-2003	O'H	ALLORAN ET AL.		
	A17	2004 115228	06-17	-2004		COSTA ET AL.		
	A18	7 445 792		-2004		TONER ET AL.		
	A19	2004 0224003		-2004		CHULTZ ET AL.		
	A20	2005 063926	03-24	-2005	BATHINA ET AL.			
	A21	2008 0102033	05-01	-2008		SPECK ET AL.		
	A22	2008 0118544	05-22	-2008	_	WANG LIXIAO		
	A23	2008 0175887	07-24	-2008	_	WANG LIXIAO		
	A24	2008 0255508		-2008	_	WANG LIXIAO		
	A25	2008 0255509	10-16	-2008	,	WANG LIXIAO		
	A26	2008 0255510	10-16	-2008	_	WANG LIXIAO		
	A27	6 682 545	01-27	-2004	К	ESTER ET AL.		
	A28	5 814 301	09-29	-1998		KLOPP ET AL.		
	A29	2008 010234	05-01	-2008		SPECK ET AL.		
			OBEIGN	PATEN	T DOCU	IMENTS		
	I	Foreign Patent Document			. 2000	Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ² - Number ⁴ - Kind (known)	Code ⁶ (if	Publicati MM-DD		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т6
	B1	JP-06-063145		03-08	-1994	KUAAYU KK		C57
	B2	JP-07-328124	_	12-19-1995		TERUMO CORP.		C58
	B3	DE-20122736		08-09	-2007	BAYER SCHERING PHARMA AG		A29
	B4	WO-03/41686		05-22		MEDLOGIC GLOBAL LTD.		
	B5	JP-2000507930)	06-27				B82
	B6	JP-10509691		09-22	-1998			B81

Considerable (In the Considerable of the Consi

Date

Considered

B17

B25

B29

R31

B30

Evamine

Signature

WO-93/09765

WO-93/09762

WO-93/11120

WO-93/11668

EP-0578998

JP-06-63145

WO-94/07529

EP-0604022

WO-94/16706

FP-0623354

WO-94/25020

WO-94/26291

DF-4334272

FP-673114

EP-0681475

JP-7-328124

PTOS.809 (69-08)
Approved for use through 1031/2086 0MB 0551/061
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to strate; availed CMB control or native

Substitute for form 1449A/PTO Complete if Known Application Number 10/528,577 INFORMATION DISCLOSURE Filing Date March 21, 2005 STATEMENT BY APPLICANT First Named Inventor Ulrich Speck et al Art I Init March 21, 2005 (Use as many sheets as necessary) Examiner Name Laura A. Bouchelle Sheet 2 Attorney Docket Number WEICKM-0044 FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines. Name of Pate Examine Where Relevant Publication Date MM-DD-YYYY Applicant of Cited Initials* No Country Gode3 - Number4 - Kind Code5 (if Passages or Relevant Document Figures Appear A28 JP-7500585 01-19-1995 Ba CORVITA EP-0357003 03-07-1990 CORP UNIV WO-90/13293 11-15-1990 SYRACUSE CEDARS SINAI MEDICAL CENTER MEDTRONIC, WO-90/13332 11-15-1990 WO-91/12779 09-05-1991 MEDTRONIC WO-91/12779 09-05-1991 MEDTRONIC, EP-0470246 02-12-1992 B12 INC BOSTON SCIENTIFIC WO-92/11896 07-23-1992 CORP WO-92/12717 08-06-1992 BREM ET AL B16 SCIMED LIFE SYSTEMS, WO-93/06792 04-05-1993 INC

05-27-1993

05-27-1993

06-10-1993

06-24-1993

01-19-1994

03-08-1994

04-14-1994

06-29-1994

08-04-1994

11-09-1994

11-10-1994

11-24-1994

04-13-1995

09-20-1995

11-15-1995

12-19-1995

"EXAMENER Initial if reference considered, whether or not distance in conformance with INETP 600 Time line through distance find in conformance and considered of conformation of the conf

Date

Considered

This collection of information is required by 37 CPR 197 and 1 8th. The information is required to offician or retain a bound by the public which is to file (and by the USPTO to process) an application for the the USPTO to process an application for the the USPTO time will very depending upon the information and info

AMSDEN ET

LONG ET AL. ZYNAXIS TECH., INC.

RUSH

PRESBYTERIAN ST. LUKE STRECKER ERNST

BUAAYU KK

NEORX CORP. ADVANCED

CARDIOVASCUL AR SYSTEMS

NEORX CORP

INC.

AB

NEORX CORP. STEMBERGER, AXEL DR

SIEMENS AG

NEORX CORP

TERUMO

CORP

A82

A10

C58

(Use as many sheets as necessary)

PTO/SB/08a (09-08) Approved for use through 10/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Laura A. Bouchelle

are required to respond to a collection of information unless it contains a valid OMB cor Under the Paperwork Reduction Act of 1995, no persons strol number Substitute for form 1449A/PTO Complete if Known Application Number 10/528,577 INFORMATION DISCLOSURE Filing Date March 21, 2005 STATEMENT BY APPLICANT First Named Inventor Ulrich Speck et al Art I Init March 21, 2005

Examiner Name

Sheet	3		of	9		Attorne	Attorney Docket Number		WEICKM-0044		
				F	OREIGN	PATEN	DOCU	MENTS			
Examiner Initials*	Cite No.1		Code3 -	t Document Number ⁴ – Kind	I Code ⁶ (#	Publicati MM-DD		Applican	atentee or t of Cited iment	Pages, Columns, Line Where Relevant Passages or Relevar Figures Appear	
	B34		EF	P-0717041		06-19-	1996	SQL BRIS MYER	JIBB STOL IS CO.		
	B36	1	EF	P-0747069		12-11-	1996	COOF	, INC.		
	B37		WC	D-97/01327		01-06	1997	MACRO	DCHEM RP.		
	B38		DE	-69119753		01-23	1997	IN	RONIC, C.		A5
	B39		W	D-97/31674		09-04	1997	SCIEN			
	B40		EF	-0797988		10-01-	1997	ANGIC	TECH, C.		
	B41			D-97/41916		11-23-	1997		CORP.		
	B42		WC	D-98/43618		10-08-	-1998	NEORX	CORP.		
	B43		WC	D-99/09729)	02-25	1999	SYSTE	KON M. INC		
	B44		W	D-99/08729)	02-25	1999	SCIEN	TÓN ITIFIC RP.		
	B45		WC	D-99/30684		06-24	1999	SUPE	RGEN.		
	B46		WC	D-99/59556	i	11-25	1999	NA			
	B47		WC	D-00/00238		01-06-	-2000	MED			
	B48		WC	D-00/00023		01-06-	-2000	HYDR			
	B49		EF	-0975340		02-02-	-2000	NEORX			B42
	B50		W	D-00/47197		08-17-	-2000	MED			
	B51		EF	P-1037605		09-27	-2000	SUPE	RGEN, C.		B45
	B52		EF	P-1090637		04-11-	-2001		TECH,		
	B53		WC	D-01/24866	,	04-12-	-2001	PENN S	T. RES.		
	B54		WC	-01/054748	В	08-02-	-2001	LIFESO	ARDS CIENCE RP.		
	B55		EF	P-1159974		12-05	-2001	ANGIO	TECH IA. INC.		
Examiner Signature							Date Consid				

EXAMINER: Initial in elerence considered, whether or not obtain a no conformance with MPEP 600. Draw line through obtain if not in conformance and not considered include copy of this form with next communication to applicant. *Applicant's unique obtained registration number (optional). *See Kinds Codes of USRYD Pathet Douments and **<u>Wave (Displage</u> or Well PO Stands 451). *For Insprince position douments, the indiscional of the layer of the Emperor must preced the senial number of the plant doublement. *Well PO Stands 451. *For Insprince position of the Stands 451. **To Stands

pièce a clock, mark fiver l'Explisi language l'arraitation a statched.

The alternation expected by 20°TH 19° and 19°C. The alternation is required to clotice or return a benefit by the public which is to fiver day the 18°TH 00 process) as river.

The collection of intermedian expected by 20°TH 19° and 19°C. The alternative is received to the increase of the control process or the complete, another gardening processing and application form to the 18°TH 01 revenue application form to the 18°TH 01 revenue and the 18°TH 01 revenue application form to the 18°TH 01 revenue application for the

Substitute for form 1449A/PTO

B70

B71

B73

B75

B76

B80

B81

B82

EP-1695698

EP-1735042

EP-1781209

WO-08/063576

WO-09/051615

WO-09/051614

WO-09/051616

WO-09/051618

EP-2092941

EP-2092942

EP-2098230

CA-2 207 025

WO-97/33552

PTO/SB/08a (09-08) Approved for use through 10/31/2008. OMB 0651-0031

Complete if Known

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Application Num	ber	10/528	3,577	
INFO	RMA	TION DI	SCLOSURE	Filing Date		March	21, 2005	
STA	ГЕМЕ	NT BY	APPLICANT	First Named Inve	entor	Ulrich Speck et al.		
				Art Unit		March	21, 2005	
	(Use as	many sheets :	as necessary)	Examiner Name		Laura	A. Bouchelle	
Sheet 4 of 9				Attorney Docket	Number	WEIC	KM-0044	
			FOREIGN	I PATENT DOCU	MENTS			
		Foreign Pat	ent Document		Name of Pate		Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code known)	³ – Number ⁴ – Kind Code ⁵ (#	Publication Date MM-DD-YYYY	Applicant o Docum	f Cited ent	Where Relevant Passages or Relevant Figures Appear	T ⁶
	B56		EP-1250166	10-23-2002	LIFE SCI COR	ENCE		B54
	B57		VO04/006976	01-22-2004	COOK,			
	B58	W	D-2004/022124	03-18-2004	ABBOTT			
	B59		EP-1407786	04-14-2004	SCIMED SYSTE	LIFE		
	B60		EP-1447098	08-08-2004	BOST SCIENT LTD	IFIC		
	B61		EP-1512398	03-09-2005	BOST SCIENT COR	IFIC		
	B62		EP-1521603	04-13-2005	COOK,			B57
	B63		EP-1536850	06-08-2005	ABBOTT			B58
	B64	W	D-2005/089855	09-29-2005	ABBOTT			
	B65		D-2006/023104	03-02-2006	BOST SCIENT COR	IFIC P.		
	B66		EP-1666070	06-07-2006	ULRICH I			A21
	B67		EP-1669091	06-14-2006	BOST SCIENT COR	IFIC P.		
	B68		EP-1695697	08-30-2006	ANGIOT	ECH,		

08-30-2006

12-27-2006

05-09-2007

05-29-2008

04-23-2009

04-23-2009

04-23-2009

04-23-2009

08-26-2009

08-26-2009

09-09-2009

06-13-1996

09-18-1997

ANGIOTECH,

INC ABBOTT LAB

BOSTON SCIENTIFIC LTD., SCIMED, INC.

LUTONIX, INC.

LUTONIX, INC.

LUTONIX, INC.

LUTONIX, INC.

WANG LIXIAO LUTONIX, INC.

LUTONIX, INC. BOSTON

LTD., SCIMED, WERNER ET

ΑI WALLACE TECH, INC. BEHRINGWER B64

B65

l	B8	2	CA-2 218 103	10-17-	1996	BEHR K	INGWER E AG	
1	Examiner Signature				Date Conside	ered		

**EXAMENT INITIAL framewor consistent either or not dution in a contemune with NEPF OD Darke through dubble find in contemune and any consistent finding of the State with their communication to positional. **Policy of the state of the contemune and search gains or a MEPF OR 16.1 **Effect for the state and the quarter of their contemune and search gains or a MEPF OR 16.1 **Effect for the state and the quarter of their contemuna and search gains and search gains

PTO/SB/08b(09-08)

Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a codedor of information unless torostins as MOR control number

Substitute for form 1449B/PTO	Complete if Known			
INFORMATION DIGGL COURT	Application Number	10/528,577		
INFORMATION DISCLOSURE	Filing Date	March 21, 2005		
STATEMENT BY APPLICANT	First Named Inventor	Ulrich Speck et al.		
	Art Unit	March 21, 2005		
(Use as many sheets as necessary)	Examiner Name	Laura A. Bouchelle		
Sheet 5 of 9	Attorney Docket Number	WEICKM-0044		

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²					
	C1	Japanese Final Rejection in Co-pending Application No. JP2004-538964 dated March 9, 2010.						
	C2	Opposition to corresponding EP1539266 by Boston Scientific Ltd., March 10, 2010.						
	C3	LIGGINS, RICHARD T, ET AL., "Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers," International Journal of Pharmaceutics, 2001, Vol. 222, pp. 19-33						
	C4	DORDUNCO, S. K. ET AL., "Release of taxol from poly(c-caprolactone) pastes: effect of water-soluble additives," Journal of Controlled Release, 1997, Vol. 44, pp. 87-94						
	C5	WICHERT, B ET AL., "Low Molecular weight PLA: a suitable polymer for pulmonary administered microparticles?" J. Microencapsulation, 1993, Vol. 10, No. 2, pp. 195-207						
	C6	NAIRN, JOHN A., "Polymer Characterization," Materials Science & Engineering 5473, 2003, Ch. 3, pp. 43-55						
	C7	LAMBA, NINA M. K. ET AL., "Structure and Physical Characterization of Polyurethanes," Polyurethanes in Biomedical Applications: Un. 4, pp.43-52						
	G8	CREMERS ET AL., "V1742 – Paclitaxel-beschictete PTCA-Katheter: Gibt es Unterschiede? Einfluss von PACCOCATH und DIOR Ballonkathetern auf die Neointimaportiferation an Schweinekoronarien," Clin. Res. Cardiol. 1992.						
	C9	CREMERS, B ET AL., "Comparison of two different pacifixel-coated balloon catheters in the porcine coronary restenceis model," Clin. Res. Cardiol., 2009, Vol. 99, pp. 325-330						
	C10	GROSSMANN, S, "Neuarlige Zubereitungen Hemmung der Neointimaproliferation in verengten Arterien," Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.), November 2016.						
	C11	SOLLOTT, STEVEN J. ET AL., 'Taxol Inhibits Neointimal Smooth Muscle Cell accumulation after angioplasty in the rat," The Journal of clinical Investigation, April 1995, Vol. 95, pp. 1869-1878						
	C12	BC, "Lippold in Retardarzneiformen" in E. Numberg, Hagers Handbuch der pharmazeutischen Praxis, Vol. 2, Springer-Verlag Berlin Heidelburg New York, 5 th edition, 1991, pp. 832-840						
	C13	LANGER, R., "New methods of drug delivery," Science, September 28, 1990, Vol. 249, pp. 1527-1533						

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a brendt by the public which is not life and by the USFTO opposes an application. Confidentiality is governed by \$6 U.S. CL 22 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case Any comments on the amount of time you require to complete the form and/or suspecients for reducing this budget, should be sent to the COME Information.

COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call *1900/FTO/99 and select oping 99 and select oping.

PTO/SB/08b(09-08)

Approved for use through 10/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless contrains a valid OMB control number.

Substitute	for form 1449B/PTC)		Complete if Known				
INITO	DALATION	DIC	OL OCUPE	Application Number	10/528,577			
			CLOSURE	Filing Date	March 21, 2005			
STAT	EMENT B	ΥA	PPLICANT	First Named Inventor	Ulrich Speck et al.			
				Art Unit	March 21, 2005			
	(Use as many she	ets as	necessary)	Examiner Name	Laura A. Bouchelle			
Sheet	Sheet 6 of 9			Attorney Docket Number	WEICKM-0044			

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т:			
	C14	KIRK-OTHMER, ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY, 3 RD Edition, Vol. 17, 1982, John Wiley & Sons, pp. 281-310				
	C15	VOIGT, R., Lehrbuch der pharmazeutishchen Technologie, 5 th edition, VEB Verlag Volk und Gesundheit Berlin, 1984, p. 689				
	C16	TAWASHI, R. "The dissolution rates of crystalline drugs," J. Mond. Pharm. 1968, Vol. 4, No. 11, pp. 371-379				
	C17	U. S. 08/094,536 (Priority of D2)				
			T			
	C18	Coomber and Gotlieb, Arterlosclerosis, 1990, Vol. 10, No. 2, pp. 215-222				
	C19	BARTOLI ET AL., J. Microencapulation, 1990, Vol. 7, No. 2, pp. 191-197				
	C20	KATSUDA ET AL., Clin. Ter. Cardiovasc. IX(4), pp. 245-248				
	C21	GARCIA-MATINEZ ET AL., "Effects of taxol on endothelial cells of the developing semilunar heart valves in the chick embryo," Acta Anat, 1988, Vol. 133, pp. 282-288				
	C22	Package Insert for Taxol				
			T			
	G23	MULLER ET AL., JACC, 1990, Vol. 17, No. 6, pp. 126B-131B				
	C24	SLEPIAN, in textbook of interventional cardiology, 1990, Section IV, Chapter 32, pp. 647-670	\vdash			

Francisco	_	$\overline{}$
Examiner	Date	1
Signature	Considered	1

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Applicants unique obtation designation number (optional). "Applicants to place a check mask here II English Iniquage Translation is attached.

This collection of Imministration required by 37 CFH 19.8. The information is required to obtation or relation a benefit by the public which is to life (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S. 0.122 and 37 CFH 1.4. This collection is estimated to take 2 hours to comprise, concluding gathering proparing, and submitting the completed application for not the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Paternation of Commence, P.O. Box 1450, Nazardin, VA 2231-1450. ON ON STEIND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Paterlay, P.O. Box 1450, Nazardin, VA 2231-1450.

If you need assistance in completing the form, cell 1-909 and select oping 9 and select oping 1000 and 1000 PTO 9 and select oping 1000 PTO 9 and 1000 PTO 9 9 PTO 9 P

PTO/SB/08b(09-08)

Approved for use through 10/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/PTC)	_	Complete if Known				
INIEO	DMATION	DIC	OL OCUPE	Application Number	10/528,577			
			CLOSURE	Filing Date	March 21, 2005			
STAT	EMENT B	ΥA	PPLICANT	First Named Inventor	Ulrich Speck et al.			
				Art Unit	March 21, 2005			
	(Use as many she	ets as	necessary)	Examiner Name	Laura A. Bouchelle			
Sheet	Sheet 7 of 9			Attorney Docket Number	WEICKM-0044			

			NON PATENT LITERATURE DOCUMENTS]
	Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, (ity and/or country where published.	T ²	
		C25	DICHEK ET AL., "Seeding of Intravascular stents with genetically engineered endothelial cells," Circulation, Vol. 80, No. 5, pp.1347-1353		1
					ľ
		C26	Single e-mail from SIGMA Chemical Company of February 15, 2007 to Dr. Sollot confirming that from 1991 – 1993 the material was listed in their catalog as "Taxol," and that the name was changed in their catalog from "tax		l
		C27	UK Court of Appeal Decision		Ļ
					ı
		C28	HIATT ET AL., "Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail,"Catheterization and Cardiovascular Interventions, 2002, Vol. 55, pp. 409-417		l
		C29	FORTH, W. ET AL. "Allegemeine und spezielle Pharmakologie und Toxikologie," 7 Auflage. Heidelberg: Spektrum Akademischer Verlag, 1996, Chapter, 1, 2, 3.		l
		C30	LIGGINS, R. T. ET AL., J. Pharma. Sci., 1997, Vol. 86, pp. 1458-1463		l
		C31	MATTHEW, R. T. ET AL., J. Med. Chem., 1992, Vol. 35, pp. 141-151		l
		C32	TARR, B. D. et al., "J. Parent Sci. Technol., 1987, Vol. 41, pp. 31-33		l
		C33	SWINDELL, C.S. ET AL., J. Med. Chem, 1991, Vol. 34, pp. 1178-1184		l
		C34	SHARMA, U. S. ET AL., J. Pharma. Sci., 1995, Vol. 84, pp. 1223-1230		l
		C35	U.S. Patent Application 08/062,451 (Priority of D3)		١
****					۲
				1	1

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicants unique existen designation unswer optional. Applicant is to place a check mark here if English language Translation is strated.

This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the UBPTO or process) an application. Confidentially is governed by \$5.U.S.O. 125. and 37 CPR 1.14. This collection is eliminated to take? It not compiles. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b(09-08) Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless its fortians a valid OMB control number.

Substitute	for form 1449B/PT0)	•		Complete if Known
INIEO	DMATION	DIC	OL OCUPE	Application Number	10/528,577
			CLOSURE	Filing Date	March 21, 2005
STAT	EMENT B	YΑ	PPLICANT	First Named Inventor	Ulrich Speck et al.
				Art Unit	March 21, 2005
	(Use as many she	ets as	necessary)	Examiner Name	Laura A. Bouchelle
Sheet	8	of	9	Attorney Docket Number	WEICKM-0044

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C36	FDA ONCOLOGY TOOLS APPROVAL SUMMARY FOR PACLITAXEL	
	C37	FDA ONCOLOGY TOOLS PRODUCT LABEL DETAILS IN CONVENTIONAL ORDER FOR PACLITAXEL	
	C38	Technical Leaflet Gremphor EL	
		Tourinear Equity Complete EL	
	C39	BARATH ET AL., JACC, 1989, Vol. 13, No 4, pp. 252A	
	C40	COX ET Al.,, Coronary Artery Disease, 1992, Vol. 3, pp. 237-248	
	C41	VOISARD ET AL., Coronary Artery Disease, 1993, Vol. 4, pp. 935-942	
	C42	Untersuchungen in vitro and in vivo, Zeitschrift fur kardiologie, Band 89, Heft 5, 2000, pp. 390-397	
	C43	Printout from the website of Bayer HealthCare Pharmaceuticals, indicating that Ultravist has been commercially available since 1985	
	C44	Report demonstrating in the C6-ceramide is a lipophilic substance as defined by the patent in suit	
	C45	MITCHEL ET AL., Circulation, October 1994, Vol. 90, pp. 1979-1988	
	C46	KANDARPA ET AL., J. Vasc. Inter. Radiol., November/ December 1997, Vol. 8, pp. 997-1004	
	C47	KANDARPA ET AL., J. Vasc. Inter. Radiol., May/ June 1998, vol. 9, pp. 487-493	
	C48	BARON ET AL., "Cardiovascular Research, June 2000, Vol. 46, pp. 585-594	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

^{*}EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant and provided include country in the communication of a provided in the conformance and not considered include copy of this form with next communication of a provided in the conformance and not c

^{&#}x27;Applicant's unique obtained designation number (optional). 'Applicant is to place a check mark here if English language Translation is allowed by ToPE 1.98. This collection of Information is required by 93 °CPE 1.98. This inclination is required to obtain or retain a benefit by the public which is to file clard by the USPTO to process) an application. Confidentiality is governed by \$5 U.S.C. 122 and 37 °CPE 1.14. This collection is estimated to take? I hours to compile the cluding gathering preparing, and submitting the completed application for not the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Pather and Trademark Office. U.S. Department of Commence, P.O. Eso 4149, Nazvandin, AV 22313-1450. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Nazvandria, VA 22313-1450.

If you need assistance in completing the form, and 14:00-PTO-1999 and select option 2.

PTO/SB/08b(09-08) Approved for use through 10/31/2008. OMB 0651-0031

Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/PT0)			Complete if Known
INIEO	DMATION	DIC	OL OCUPE	Application Number	10/528,577
			CLOSURE	Filing Date	March 21, 2005
STAT	EMENT B	YΑ	PPLICANT	First Named Inventor	Ulrich Speck et al.
				Art Unit	March 21, 2005
	(Use as many she	ets as	necessary)	Examiner Name	Laura A. Bouchelle
Sheet	9	of	9	Attorney Docket Number	WEICKM-0044

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1						
	C49	Office Action issued by the European Patent Office on September 15, 2005					
	C50	Claims enclosed with Office Action issued by European Patent Office on September 15, 2005					
	C51	Response filed on January 13, 2006					
***************************************	C52	Product Information on the DIOR balloon catheter from Eurocor GmbH					
	C53	Copy of the decision to revoke EP1140273 B1 (=D11EP) of October 23, 2007					
	C54	Gincal Cardiology Divergent Effects on Coronary Artery Disease: Abstract from 70 th Scientific Session: Circulation, Vol. 96, no. 8, October 21, 2007					
	C55	Definition of "partition coefficient" Wikipedia					
	C56	KHAN, I ET AL., Drug Development and Industrial Pharmacy, 2005, Vol. 31, pp. 59-78					
	C57	BUAAYK KK, "Balloon Catheter for Intravascular Dosing," Patent Abstracts of Japan, Publication Date: March 8, 1994, English Abstract of JP06-063145					
	C58	TERUMO CORP, "Medicine dosing catheter," Patent Abstracts of Japan, Publication Date: December 19, 1995, English Abstract of JP07-328124					

Signature /Laura Bouchelle/	Considered 07/30/2010
-----------------------------	-----------------------

^{*}EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

*Applicant is unjudice obtained designation number (postboan). *Applicant is on place of applicant.

07/00/00/0

Applicants unique oftom designation number (optional). Applicant is to place a check mark here it brights introduced in a fraction is attached.

This collection of introduced in a bright of the property of the collection of the property o